Home > Dermatology > Baricitinib plus corticosteroids effectively treats atopic dermatitis

Baricitinib plus corticosteroids effectively treats atopic dermatitis

JAMA Dermatology
Reuters Health - 09/10/2020 - The Janus kinase inhibitor baricitinib, in combination with topical corticosteroids (TCS), improved refractory moderate-to-severe atopic dermatitis (AD) in a phase-3 trial. "This improvement in skin inflammation was achieved with the 4-mg dose while simultaneously reducing the amount of topical corticosteroids patients," Dr. Kristian Reich of University Medical Center Hamburg-Eppendorf told Reuters Health by email. "This corticosteroid-sparing function will play an important role in clinical practice, where patients with moderate-to-severe AD already present inadequate response to TCS, despite use of a significant amount of moderate- and high- potency TCS on their extensive skin lesions." As reported in JAMA Dermatology, 329 patients (mean age, 34; 66% men) were recruited from 68 centers across 10 countries in Asia, Australia, Europe and South America. All had moderate-to-severe AD refractory to TCSs. After completing the study, they we...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on